IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Charles L. Sawyers et al. Art Unit; 1642

Application No: 10/583,280 Examiner: Sean E. Aeder

Confirmation No: 2639

Filed: June 16, 2006 Atty. Docket No: 58086-232451

Customer No: For: METHOD AND MATERIALS FOR

METHOD AND MATERIALS FOR 26694
ASSESSING PROSTATE CANCER PATENTIFACIBMARK OFFICE
THERAPIES

SUBMISSION OF CORRECTED INFORMATION DISCLOSURE STATEMENT DOCUMENTS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir/Madam:

In the course of reviewing documents on the U.S. Patent and Trademark Office (USPTO) electronic PAIR system for the above-identified application, Applicant noted a typographical error on an SB/08 form submitted with the Information Disclosure Statement (IDS) filed November 1, 2007. Applicant herewith submits a replacement page 3 of the SB/08 of the November 1, 2007 IDS correcting citation number C15 (Jones). Applicant requests that the citation be corrected in the systems of the USPTO and appear on any publication or patent to issue from the above-identified application. The correction is shown by underlining and strikethrough below:

[C15, IDS of Nov. 1, 2007] **Jones, Genetics, 85:12 23 (1977).**

Applicant further noted that a document submitted with an IDS had a page missing. For the citation C18 (Balk), listed with the IDS filed November 1, 2007, the corresponding document has page 139 missing. The complete document for citation C18 (Balk, Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002. v. 60, pp. 132-139) is enclosed with this paper. Applicant respectfully requests that the complete document be expressly considered during the prosecution of this application, and that the document be made of record therein and appear on any patent to issue therefrom.

This submission is associated with a supplemental Information Disclosure Statement made for the above-identified application on this same day, March 17, 2010, and Applicant understands that no additional fee is required. The Commissioner is authorized to charge any deficiency in any patent application processing fees associated with this communication and any other communication filed by this law firm for the above-identified application and to credit any excess payment to Deposit Account No. 22-0261, under Order Number 58086-232451.

Dated: March 17, 2010 Respectfully submitted,

Ву

Lars H. Genieser Registration No.: 46,722 VENABLE LLP P.O. Box 34385 Washington, DC 20043-9998 (202) 344-4000 (202) 344-8300 (Fax)

Attorney/Agent For Applicant

DC2/1095953